-Advertisement-
-Advertisement-
Retina

Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD

Posted on July 19, 2021
biosimilar

A biosimilar of ranibizumab has a comparable efficacy and safety profile to the reference product in the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD), according to a study undertaken for regulatory purposes. No meaningful clinical difference was found between the biosimilar and reference product.

At week 16, 98.11% of patients in the biosimilar test arm lost <15 letters in visual acuity compared with 100% in the reference arm. At week 24, 99.06% of patients in the biosimilar test arm lost <15 letters in visual acuity compared with 100% in the reference arm.

At least 15 letters in visual acuity till week s16 and 24 were gained in 25.47% and 32.08% and 32.08% and 43.30% of patients in the test arm and reference arm, respectively.

Mean change in central macular thickness at 24 weeks was − 89.93 μm in the biosimilar test arm and − 64.42 μm in the reference arm.

 There was no statistically significant difference for any endpoint at weeks 16 and 24.

Reference
Apsangikar P, Ghadge P, Naik M, et al. Double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (wet) age-related macular degeneration. Clin Ophthalmol. 2021;15:3087-3095. https://doi.org/10.2147/OPTH.S307746

-Advertisement-
Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
FDA grants breakthrough therapy designation for ALK-001 for Stargardt Disease
Jul 15, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-